Prevalence of atrial fibrillation and warfarin use in older patients receiving hemodialysis

Journal of Nephrology

Volumn 25, Issue 3, 2012, Pages 341-353

  Winkelmayer, Wolfgang C ^a,b   Liu, Jun ^a   Patrick, Amanda R ^a   Setoguchi, Soko ^a,c   Choudhry, Niteesh K ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c DUKE CLINICAL RESEARCH INSTITUTE   (United States)

Author keywords

Anticoagulation; Arrhythmia; Drug utilization; End stage renal disease

Indexed keywords

WARFARIN;

AGED; AGING; ARTICLE; CLINICAL FEATURE; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DEMOGRAPHY; FEMALE; HEALTH CARE UTILIZATION; HEART ATRIUM FIBRILLATION; HEMODIALYSIS PATIENT; HUMAN; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MEDICARE; PRESCRIPTION; PREVALENCE; RACE DIFFERENCE; UNITED STATES;

AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ATRIAL FIBRILLATION; DRUG PRESCRIPTIONS; DRUG UTILIZATION; HUMANS; KIDNEY FAILURE, CHRONIC; LOGISTIC MODELS; MEDICARE; MULTIVARIATE ANALYSIS; NEW JERSEY; ODDS RATIO; PENNSYLVANIA; PREVALENCE; RENAL DIALYSIS; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; UNITED STATES; WARFARIN;

EID: 84863312654     PISSN: 11218428     EISSN: 17246059     Source Type: Journal    
DOI: 10.5301/jn.5000010     Document Type: Article

References (25)

1. Wizemann V, Tong L, Satayathum S, et al. Atrial fibrillation in hemodialysis patients: clinical features and associations with anticoagulant therapy. Kidney Int. 2010;77(12): 1098-1106.
2. Winkelmayer WC, Patrick AR, Liu J, Brookhart MA, Setoguchi S. The increasing prevalence of atrial fibrillation among hemodialysis patients. J Am Soc Nephrol. 2011;22(2):349-357.
3. Seliger SL, Gillen DL, Longstreth WT Jr, Kestenbaum B, Stehman-Breen CO. Elevated risk of stroke among patients with end-stage renal disease. Kidney Int. 2003;64(2):603-609.
4. Fuster V, Rydén LE, Asinger RW, et al; American College of Cardiology/American Heart Association Task Force on Practice Guidelines; European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation); North American Society of Pacing and Electrophysiology. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: executive summary. A Report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation) developed in collaboration with the North American Society of Pacing and Electrophysiology. Circulation. 2001;104(17):2118-2150.
5. Fuster V, Rydén LE, Cannom DS, et al; Heart Rhythm Society. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients with Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation. 2006;114(7):e257-e354.
6. Bennett WM. Should dialysis patients ever receive warfarin and for what reasons? Clin J Am Soc Nephrol. 2006;1(6): 1357-1359.
7. Vázquez E, Sánchez-Perales C, García-Cortes MJ, et al. Ought dialysis patients with atrial fibrillation be treated with oral anticoagulants? Int J Cardiol. 2003;87(2-3):135-139, discussion 139-141.
8. Quinn RR, Naimark DM, Oliver MJ, Bayoumi AM. Should hemodialysis patients with atrial fibrillation undergo systemic anticoagulation? A cost-utility analysis. Am J Kidney Dis. 2007;50(3):421-432.
9. Chan KE, Lazarus JM, Thadhani R, Hakim RM. Warfarin use associates with increased risk for stroke in hemodialysis patients with atrial fibrillation. J Am Soc Nephrol. 2009;20(10): 2223-2233.
10. Wiesholzer M, Harm F, Tomasec G, Barbieri G, Putz D, Balcke P. Incidence of stroke among chronic hemodialysis patients with nonrheumatic atrial fibrillation. Am J Nephrol. 2001;21(1):35-39.
11. Wasse H, Gillen DL, Ball AM, et al. Risk factors for upper gastrointestinal bleeding among end-stage renal disease patients. Kidney Int. 2003;64(4):1455-1461.
12. Elliott MJ, Zimmerman D, Holden RM. Warfarin anticoagulation in hemodialysis patients: a systematic review of bleeding rates. Am J Kidney Dis. 2007;50(3):433-440.
13. Fang MC, Stafford RS, Ruskin JN, Singer DE. National trends in antiarrhythmic and antithrombotic medication use in atrial fibrillation. Arch Intern Med. 2004;164(1):55-60.
14. Lakshminarayan K, Solid CA, Collins AJ, Anderson DC, Herzog CA. Atrial fibrillation and stroke in the general Medicare population: a 10-year perspective (1992 to 2002). Stroke. 2006;37(8):1969-1974.
15. Yan Y, Birman-Deych E, Radford MJ, Nilasena DS, Gage BF. Comorbidity indices to predict mortality from Medicare data: results from the national registry of atrial fibrillation. Med Care. 2005;43(11):1073-1077.
16. Kokotailo RA, Hill MD. Coding of stroke and stroke risk factors using International Classification of Diseases, revisions 9 and 10. Stroke. 2005;36(8):1776-1781.
17. Lentine KL, Schnitzler MA, Abbott KC, Bramesfeld K, Buchanan PM, Brennan DC. Sensitivity of billing claims for cardiovascular disease events among kidney transplant recipients. Clin J Am Soc Nephrol. 2009;4(7):1213-1221.
18. Choudhry NK, Anderson GM, Laupacis A, Ross-Degnan D, Normand SL, Soumerai SB. Impact of adverse events on prescribing warfarin in patients with atrial fibrillation: matched pair analysis. BMJ. 2006;332(7534):141-145.
19. Lentine KL, Schnitzler MA, Abbott KC, et al. Incidence, predictors, and associated outcomes of atrial fibrillation after kidney transplantation. Clin J Am Soc Nephrol. 2006;1(2): 288-296.
20. Choudhry NK, Soumerai SB, Normand SL, Ross-Degnan D, Laupacis A, Anderson GM. Warfarin prescribing in atrial fibrillation: the impact of physician, patient, and hospital characteristics. Am J Med. 2006;119(7):607-615.
21. National Kidney Foundation. KDOQI clinical practice guidelines for cardiovascular disease in dialysis patients: Section I: guidelines on evaluation and management of cardiovascular diseases. Guideline 9: cerebrovascular disease. 2005. Available at: http://www.kidney.org/professionals/KDOQI/guidelines_ cvd/guide9.htm. Accessed January 5, 2011.
22. Ray WA. Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol. 2003;158(9):915-920.
23. Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA. 2001;285(18):2370-2375.
24. Wattigney WA, Mensah GA, Croft JB. Increasing trends in hospitalization for atrial fibrillation in the United States, 1985 through 1999: implications for primary prevention. Circulation. 2003;108(6):711-716.
25. Khairallah F, Ezzedine R, Ganz LI, London B, Saba S. Epidemiology and determinants of outcome of admissions for atrial fibrillation in the United States from 1996 to 2001. Am J Cardiol. 2004;94(4):500-504.